ECC Cases
Case Vignettes: Managing Cardiovascular Risk in HIV-Infected Patients
Cases
Managing Lipoatrophy in a Stable HIV-Infected Patient on Stavudine
|
|
|
 In a case-based discussion, William G. Powderly, MD, reviews considerations for managing lipoatrophy in a patient stable on a stavudine-containing regimen for several years. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss potential causes and the prevalence of lipoatrophy in HIV-infected patients
- Describe the impact on limb fat of switching from a thymidine analogue to abacavir or tenofovir
- Outline considerations when switching to abacavir in patients previously on dual- or mono-NRTI therapy
|
An HIV-Infected Patient With Dyslipidemia Despite Ongoing Statin Therapy
|
|
|
William G. Powderly, MD, presents a case-based discussion of management strategies for dyslipidemia in patients receiving antiretroviral therapy. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss trends in morbidity and mortality among HIV-infected patients
- Identify potential causes of lipid dysregulation in HIV-infected patients
- Describe strategies for managing dyslipidemia in HIV-infected patients
|
Management of Insulin Resistance in an HIV-Infected Patient
|
|
|
Sally Hodder, MD, presents a case-based discussion of management strategies for insulin resistance in a highly treatment–experienced HIV-infected patient. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the definition and prevalence of impaired glucose tolerance in HIV-infected patients
- Describe the role of diet and exercise in HIV-infected patients with insulin resistance
- Compare and contrast the effects of metformin and rosiglitazone on insulin sensitivity, body composition, and lipid levels in HIV-infected patients with lipodystrophy
|
Assessing Targets for LDL Cholesterol Reduction in an HIV-Infected Patient
- Marshall J. Glesby, MD, PhD
|
|
|
Marshall J. Glesby, MD, PhD, discusses optimal targets for LDL cholesterol in individuals with HIV infection using CCO’s popular case-based format. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe recommended targets for low density lipoprotein cholesterol
- Discuss data on the incidence of coronary heart disease in HIV-infected patients
- Describe strategies for lowering low density lipoprotein cholesterol in HIV-infected patients
|
Antiretroviral Selection and Use of Lipid-Lowering Agents in a Patient With a Recent Myocardial Infarction
|
|
|
Management decisions concerning lipid control following an MI reviewed in this short case study by William G. Powderly, MD. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the effects of antiretroviral agents on lipid levels in HIV-infected patients
- Describe data on management of dyslipidemia in HIV-infected patients
- Explain interactions between antiretrovirals and lipid-lowering drugs
|
Metabolic Complications in an HIV/HCV-Coinfected Patient
|
|
|
Review data on predictors and management of insulin resistance and diabetes mellitus in patients with HIV/HCV coinfection in this case vignette by Sally Hodder, MD. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss epidemiological data describing predictors of diabetes in patients with HCV infection
- Describe metabolic factors associated with fibrosis in HCV-infected patients
- Discuss data on the prevalence of insulin resistance and/or diabetes in patients with HIV/HCV coinfection compared with HIV-monoinfected patients
|
Management of Visceral Fat Accumulation in an HIV-Infected Man
|
|
|
Donald P. Kotler, MD, reviews the case of an HIV-infected patient with long-term visceral adiposity during PI-based therapy, and discusses potential management strategies. Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize the patterns of fat gain and fat loss reported in patients with HIV infection
- Discuss clinical data on the impact of different antiretroviral regimens on visceral fat quantities in HIV-infected patients
- Describe the results of clinical studies of recombinant human growth hormone as a treatment for visceral fat accumulation in HIV-infected patients
|
Management of Hypertriglyceridemia in an HIV-Infected Woman
- Marshall J. Glesby, MD, PhD
|
|
|
Marshall J. Glesby, MD, PhD, presents a short case study describing an HIV-infected patient with isolated hypertriglyceridemia and management options in relation to cardiovascular disease risk. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the management of hypertriglyceridemia in patients with HIV infection
- Describe the effects of fish oil supplementation on lipid levels
- Summarize data from clinical trials of the use of niacin in HIV-infected patients
|
First-Line Antiretroviral Selection for a Patient at Moderate Risk of Cardiovascular Disease
|
|
|
William G. Powderly, MD, reviews considerations when choosing among different antiretroviral agents as first-line therapy for patients at moderate risk of cardiovascular disease. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe cardiovascular risk factors commonly observed in HIV- infected patients and strategies for minimizing cardiovascular risk
- Review data on the lipid impact of different antiretroviral regimens
- Discuss strategies for individualizing the use of antiretroviral agents to manage dyslipidemia in HIV-infected patients
|
Role of Exercise in the Management of HIV-Associated Lipodystrophy
|
|
|
Dominic Reeds, MD, reviews the role of aerobic exercise in the treatment of patients with HIV-associated lipodystrophy. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss data on the impact of exercise on lipids and insulin sensitivity in patients with HIV-associated lipodystrophy
- Discuss data on the impact of exercise on body composition and fat distribution in patients with HIV-associated lipodystrophy
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|